Search PubMed⌕ Search

Biomedical subjects

C Sauter

Publications and source records attributed to C Sauter.

At least 91 records · Page 5Linked to original sources
PubMed1986

Interactions of cytotoxic and other drugs: rapid cell culture assay.

In order to investigate the interactions of cytotoxic and other drugs, a cell culture assay was devised where changes in the ability of cytotoxic drugs to induce cytopathogenic effects can easily be visualized. A human mammary carcinoma cell line (BT 20) and a human hypernephroma cell line were used. Seventeen commonly used cytotoxic drugs were titrated in this assay. As an example of drug interactions the neutralization of nitrogen mustard, cis-dichlorodiammine-platinumII, and 4-hydroperoxycyclophosphamide by thiol-containing drugs shows that this assay is well suited to detect interactions of cytotoxic and other drugs.

Antineoplastic Agents↗
PubMed1986

Efficacy and clinical cross-resistance of a new combination therapy (AMSA/VP16) in previously treated patients with acute nonlymphocytic leukemia.

We investigated the tolerance, efficacy, and clinical cross-resistance of a new combination chemotherapy in 38 patients with previously treated acute myeloblastic leukemia (AML). It consisted of 120 mg2/d 4'(9-acridinylamino) methanesulfon-m-Anisidide (m-AMSA) in a one-hour infusion and 80 mg/m2/d etoposide (VP-16) in a 24-hour infusion, both administered for 5 days. The first 27 patients also received vinblastine, 6 mg/m2 on day 8, but this therapy was discontinued because of intestinal complications. Thirteen of 23 patients (56%) at first or subsequent relapse and five of 15 patients (33%) who were primarily resistant to an anthracycline/cytarabine combination achieved a complete response (CR) (hemoglobin level not taken into account) with a median CR duration of 5 months and 2 months, respectively. The response rate was as high as 63% for patients at first or second relapse whether the remission was maintained or not. The median times to recovery of normal bone marrow cellularity, of blood granulocyte counts greater than 500/microL, and of platelets greater than 20,000/microL were 34, 27, and 22 days, respectively. Marked but reversible gastrointestinal toxicity was observed in 24% of the patients, and two patients died of infection during induction. The one-hour AMSA/continuous VP-16 combination is effective for patients with relapsing AML and shows no cross-resistance in a proportion of patients refractory to the standard anthracycline-cytarabine combination.

Adolescent↗
PubMed1985

[Hypercalcemia in non-Hodgkin lymphoma].

In a retrospective study, hypercalcemia was found on one or more occasions in 14 of 156 patients with newly detected, still active or relapsing non-Hodgkin's lymphoma (NHL). The incidence of hypercalcemia correlated with the histological grade of malignancy: patients with high grade NHL had a hypercalcemia incidence of 23%. Half of the patients had hypercalcemia-related symptoms, and 4 of 14 had hypercalcemia-induced renal impairment. The occurrence or recurrence of hypercalcemia correlated with progression of NHL. Remission-inducing chemotherapy and symptomatic treatment of hypercalcemia corrected the serum calcium.

Antineoplastic Agents↗
PubMed1985

[Effect of interferon-alpha 2 (E. coli) in hairy cell leukemia].

Recombinant interferon-alpha 2 (E. coli) produced a clinically significant improvement in hemoglobin, granulocytes and platelets in 7 of 8 patients with hairy cell leukemia. Response to treatment was already noticeable in the fourth treatment week. In one case without improvement after 120 days, treatment was stopped. So far only one complete remission has been documented. Because of the remarkable improvement in the peripheral blood values, the induction of a complete remission may not be the ultimate goal of interferon treatment. The side effects of this subcutaneous low-dose treatment consisted mainly of mild flu-like symptoms of short duration. The results obtained with recombinant interferon-alpha 2 confirm the initial observation by Quesada et al. with partially purified leukocyte-interferon. In our experience, these results are superior to those obtained in similar conditions with chlorambucil.

Adult↗
PubMed1985

Hairy cell leukemia: an interferon deficient disease?

rIFN-alpha 2 is an effective substance in the treatment of HCL. Although the complete eradication of hairy cells from the bone marrow is rarely possible, a dramatic improvement of profound cytopenias can be obtained in most patients, 12 out of 13 in this study. The response can be seen after a median treatment duration of about 2 months and appears to be independent of the presence of the spleen. Once a stable improvement of the peripheral blood values is achieved, one dose of rIFN-alpha 2 every other week may be sufficient to maintain the cell counts. The mechanism(s) by which IFN acts remain unclear. We speculate, that HCL is an IFN deficient syndrome because monocytes which are the major source of IFN-alpha are severely depressed in this lymphoproliferative disorder. Following this hypothesis, the IFN therapy would be comparable to the substitution of insulin in diabetic patients.

Adult↗
PubMed1984

Acute myelogenous leukaemia: maintenance chemotherapy after early consolidation treatment does not prolong survival.

To investigate the value of maintenance chemotherapy after early consolidation treatment, an attempt was made to induce remission in 162 previously untreated patients, age-range 7-65 years (median 43). The 74 patients who were still in remission after early consolidation treatment (given for 3-5 months) were assigned to either maintenance chemotherapy every 8 weeks for 2 years or to observation only. After a median observation period of 44 months there was no difference between the groups in duration of remission or survival. Surprisingly, patients above 40 survived longer after early consolidation (median 4 years) than did patients aged 40 and below (median 1.6 years, p = 0.0002).

Adolescent↗
PubMed1984

Phase-II study of vindesine and hexamethylmelamine in patients with relapsing small cell carcinoma of the lung.

Twenty-five patients with measurable small cell lung cancer relapsing after first-line chemotherapy were treated with vindesine 3 mg/m2 IV on days 1 and 8 and hexamethylmelamine 100 mg/m2 PO on days 1-14, repeated every 3 weeks. Among 18 fully evaluable patients there was 1 partial remission lasting for 111 days. Two patients had disease stabilization for 127 and 152 days, respectively. Fifteen patients had disease progression. The treatment was well tolerated, myelosuppression being the major side-effect.

Adult↗
PubMed1984

Phase II trial of mitomycin-C in patients with small cell carcinoma of the lung after failure on combination chemotherapy.

Mitomycin-C was evaluated in a disease-oriented phase II trial in patients with small cell lung cancer who had failed prior conventional chemotherapy. The drug was given as a direct i.v. injection of 15 mg/m2 repeated every 6 weeks. No objective tumor response was observed among 15 evaluable patients. This precludes a 20% level of activity with 95% confidence. Leukopenia (60% of patients) and thrombocytopenia (20% of patients) were common-effects observed. One patient developed a microangiopathic hemolytic anemia after a total mitomycin-C dose of 42 mg. We conclude that mitomycin-C in this dose and schedule is an inactive agent in previously treated patients with small cell lung cancer.

Adult↗
PubMed1983

[Has current adjuvant cytostatic therapy in radically operated breast cancer patients failed?].

Ten years ago the first adjuvant study with combination chemotherapy for radically mastectomized mammary carcinoma patients was implemented. The results today show that 12 months' treatment with cyclophosphamide, methotrexate and 5-fluorouracil does not prolong survival. In the group of premenopausal women with 1 to 3 histologically positive axillary lymph nodes a lengthening of the time to relapse was observed (in 20% of the patients), but with no prolongation of survival. In the light of these results the ongoing Swiss trials should be reevaluated.

Antineoplastic Agents↗
PubMed1983

Early antiviral antibody response after immunization with viral oncolysate: a powerful prognostic marker for acute myelogenous leukemia remission patients.

Twenty-four acute myelogenous leukemia (AML) patients in first clinical remission received, as a part of their maintenance therapy, repeated injections of viral oncolysate (i.e., avian influenza virus-infected, formalin-inactivated, allogeneic leukemia cells). The anti-oncolysate-virus antibody responses after a single injection, tested by a radioimmunoassay, were in inverse correlation to the remission duration (p less than or equal to 0.01). The 25% of patients with the lowest responses had a median remission duration of more than 36 mo, with no relapses within the first 18 mo. In contrast, the 75% of patients with higher responses had a median remission time of less than 5 mo, and more than 80% relapsed within 18 mo. Despite the small number of patients, these differences are highly significant (p less than or equal to 0.001). Immunization of remission AML patients with viral oncolysate provides a powerful prognostic test. Most early relapses can be predicted, with a modest rate of false-positive and false-negative predictions.

Antibodies, Viral↗
PubMed1983

Delayed alloimmunization using random single donor platelet transfusions: a prospective study in thrombocytopenic patients with acute leukemia.

A randomized study was performed in 54 thrombocytopenic patients with acute leukemia. Alloimmunization of recipients of random multiple-donor platelet concentrates (MD group) was compared to that of patients receiving random single-donor platelets (SD group). In the SD patients, formation of alloantibodies (mostly anti-HLA) occurred less frequently (p less than 0.002), after a longer time period (p less than 0.002), and after a higher number of transfusions (p less than 0.005) as compared to MD patients. SD patients also became refractory to random platelets less frequently (p less than 0.005), after a longer time period, and after a higher number of transfusions (p less than 0.02). In SD patients, the increments after the first and the last transfusion were in the same range, whereas in MD patients, the 1-hr (p less than 0.001) and the 24-hr (p less than 0.025) increments decreased from the first to the last transfusion. Thus, the use of random SD platelet transfusions postponed alloimmunization.

Acute Disease↗
PubMed1982

Acute myelogenous leukemia: successful treatment of relapse with cytosine arabinoside, VP 16-213, vincristine and vinblastine (A-triple-V).

Between March 1980 and January 1982, 15 patients with acute myelogenous leukemia (AML) in relapse were treated with one or more cycles of a combination chemotherapy consisting of cytosine arabinoside (Ara-C), VP 16-213, vincristine and vinblastine (A-triple-V). Of a total of 20 treatment cycles given, one partial and 15 complete remissions were achieved, there was no change in the bone marrow in two cases, one patient died due to Pseudomonas septicemia during an apparently normal bone marrow regeneration and one patient died of Candida infection while in aplasia. With 15 out of 20 (75%) successful relapse treatment courses, A-triple-V should be tested in first-line protocols.

Adult↗
PubMed1981

Inverse correlation of antiviral antibody titers and the remission length in patients treated with viral oncolysate: a possible new prognostic sign in acute myelogenous leukemia.

In a study conducted since August 1974 by the Swiss Group for Clinical Cancer Research, 57 of 107 patients suffering from acute myelogenous leukemia achieved a complete remission. Thirty of these 57 patients were randomly selected to receive maintenance chemotherapy alone; the other 27 patients received, in addition to the same chemotherapy, monthly injections of viral oncolysate (i.e., formalin-treated fowl plaque virus-infected allogenous leukemia cells). The levels of antifowl plaque virus antibody titers in the sera were determined at regular intervals. All patients with an initial antibody titer of zero and a titer increase after the very first injection of oncolysate had remission times of less than six months (P less than or equal to 0.02). After the fifth injection there wa a clear reverse correlation of titer values and remission lengths (P less than or equal to 0.01). Several patients showed an association of changes of antiviral antibodies in the serum and the percentage of myeloblasts in the bone marrow. Immunization by viral oncolysate can therefore be used to predict the course of patients who are in remission from acute myelogenous leukemia; it may furthermore be helpful in detecting patients whose treatment has been insufficient.

Antibodies, Viral↗